Director George Kemble Sells $3.6M in Sagimet Stock Under 10b5-1 Plan
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Director George Kemble sold $3.6M of Sagimet stock at $10.23 after exercising options at $6.36, under a pre-existing 10b5-1 plan.
Key Events · Ownership and Investor Activity · SGMT
-
Director Sells $3.6M in Stock
George Kemble sold 350,987 shares at $10.23 on August 14, 2026, for total proceeds of $3,591,580.
-
Option Exercise Precedes Sale
Kemble exercised 350,987 options at $6.36 per share, paying $2,232,277, and immediately sold the shares at market price.
-
10b5-1 Plan Execution
The sale was executed under a Rule 10b5-1 trading plan adopted on August 21, 2025, indicating it was pre-planned.
-
Larger Than Prior Notice
The sale is significantly larger than the 18,844 shares noticed in a Form 144 filed on July 20, 2026.
Analysis · SGMT · Life Sciences
Director George Kemble exercised options for 350,987 shares at $6.36 and immediately sold them at $10.23, realizing $3.6 million. The sale was executed under a pre-existing 10b5-1 plan adopted in August 2025, so it was pre-planned and not a reaction to recent news. However, the size is notable: the sale represents 0.55% of the company's market cap and is significantly larger than the 18,844 shares noticed in the July 20 Form 144. This is part of a broader insider distribution pattern, with three insiders selling over $920K in the last 90 days.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.5% of the 1575 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMT was trading at $10.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $638.2M. The 52-week trading range was $4.50 to $11.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.